Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia

W. van den Ancker; M.M. van Luijn; T.M. Westers; H.J. Bontkes; J.M. Ruben; T.D. de Gruijl; G.J. Ossenkoppele; A.A. van de Loosdrecht

doi:https://doi.org/10.2217/imt.09.85

Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia

W. van den Ancker, M.M. van Luijn, T.M. Westers, H.J. Bontkes, J.M. Ruben, T.D. de Gruijl, G.J. Ossenkoppele, A.A. van de Loosdrecht

Research output: Contribution to journal › Article › Academic › peer-review

22 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	69-83
Journal	Immunotherapy
Volume	2
Issue number	1
DOIs	https://doi.org/10.2217/imt.09.85
Publication status	Published - 2010

Access to Document

https://doi.org/10.2217/imt.09.85

Cite this

@article{3ca566fa69f74708a985d3ce04aa2800,

title = "Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia",

author = "{van den Ancker}, W. and {van Luijn}, M.M. and T.M. Westers and H.J. Bontkes and J.M. Ruben and {de Gruijl}, T.D. and G.J. Ossenkoppele and {van de Loosdrecht}, A.A.",

year = "2010",

doi = "https://doi.org/10.2217/imt.09.85",

language = "Undefined/Unknown",

volume = "2",

pages = "69--83",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia

AU - van den Ancker, W.

AU - van Luijn, M.M.

AU - Westers, T.M.

AU - Bontkes, H.J.

AU - Ruben, J.M.

AU - de Gruijl, T.D.

AU - Ossenkoppele, G.J.

AU - van de Loosdrecht, A.A.

PY - 2010

Y1 - 2010

U2 - https://doi.org/10.2217/imt.09.85

DO - https://doi.org/10.2217/imt.09.85

M3 - Article

C2 - 20635890

SN - 1750-743X

VL - 2

SP - 69

EP - 83

JO - Immunotherapy

JF - Immunotherapy

IS - 1

ER -